{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T02:22:33Z","timestamp":1791426153890,"version":"4.3.3"},"update-to":[{"DOI":"10.1002\/14651858.cd010770","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2017,4,26]],"date-time":"2017-04-26T00:00:00Z","timestamp":1493164800000}}],"reference-count":95,"publisher":"Wiley","issue":"4","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd010770.pub2","type":"journal-article","created":{"date-parts":[[2017,4,26]],"date-time":"2017-04-26T03:36:44Z","timestamp":1493177804000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":44,"title":["Selective progesterone receptor modulators (SPRMs) for uterine fibroids"],"prefix":"10.1002","volume":"2017","author":[{"given":"Ally","family":"Murji","sequence":"first","affiliation":[{"name":"Mount Sinai Hospital, University of Toronto; Department of Obstetrics and Gynecology; 700 University Ave - 3rd Floor Toronto ON Canada M5G 1Z5"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucy","family":"Whitaker","sequence":"additional","affiliation":[{"name":"Royal Infirmary of Edinburgh; Simpson Centre for Reproductive Health; 51 Little France Crescent Old Dalkeith Road Edinburgh UK EH16 4SA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiffany L","family":"Chow","sequence":"additional","affiliation":[{"name":"University of Toronto; 27 King's College Circle Toronto Ontario Canada M5S 1A1"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mara L","family":"Sobel","sequence":"additional","affiliation":[{"name":"Mount Sinai Hospital, University of Toronto; Department of Obstetrics and Gynecology; 700 University Ave - 3rd Floor Toronto ON Canada M5G 1Z5"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2017,4,26]]},"reference":[{"key":"10.1002\/14651858.CD010770.pub2-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1111\/j.1479-828X.2008.00931.x","article-title":"Low-dose mifepristone in treatment of uterine leiomyoma: a randomised double-blind placebo-controlled clinical trial","volume":"49","author":"Bagaria","year":"2009","journal-title":"Australian and New Zealand Journal of Obstetrics and Gynaecology"},{"key":"10.1002\/14651858.CD010770.pub2-BIB0002|cit2","first-page":"119","article-title":"Progesterone preoperative treatment for myomectomy with the intrauterine bigatti shaver (IBS)","volume":"1","author":"Bigatti","year":"2014","journal-title":"Gynecological Surgery"},{"key":"10.1002\/14651858.CD010770.pub2-BIB0003|cit3","doi-asserted-by":"crossref","unstructured":"Chwalisz K Larsen L Edmonds A Winkel C Effectiveness of asoprisnil, a selective progesterone receptor modulator (SPRM) in treating uterine leiomyomata Advances in Uterine Leiomyoma Research: 2nd NIH International Congress 2005","DOI":"10.1201\/b14628-27"},{"key":"10.1002\/14651858.CD010770.pub2-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1016\/j.fertnstert.2006.11.094","article-title":"A randomized, controlled trial of asoprisnil, a novel selective progesterone receptor modulator, in women with uterine leiomyomata","volume":"87","author":"Chwalisz","year":"2007","journal-title":"Fertility and Sterility"},{"key":"10.1002\/14651858.CD010770.pub2-BIB0005|cit5","first-page":"320A","article-title":"Effects of the novel selective progesterone receptor modulator (SPRM) asoprisnil on bleeding patterns in subjects with leiomyomata","volume":"11","author":"Chwalisz","year":"2004","journal-title":"Journal of the Society for Gynecologic Investigation"},{"key":"10.1002\/14651858.CD010770.pub2-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1177\/1933719112463252","article-title":"Validation of the menstrual pictogram in women with leiomyomata associated with heavy menstrual bleeding","volume":"20","author":"Larsen","year":"2013","journal-title":"Reproductive Sciences (Thousand Oaks, Calif.)"},{"key":"10.1002\/14651858.CD010770.pub2-BIB0007|cit7","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1093\/humrep\/det467","article-title":"Individualized vaginal bleeding experience of women with uterine fibroids in the PEARL I randomized controlled trial comparing the effects of ulipristal acetate or placebo","volume":"29","author":"Barlow","year":"2014","journal-title":"Human Reproduction"},{"key":"10.1002\/14651858.CD010770.pub2-BIB0008|cit8","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1056\/NEJMoa1103182","article-title":"Ulipristal acetate versus placebo for fibroid treatment before surgery","volume":"366","author":"Donnez","year":"2012","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD010770.pub2-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1097\/PGP.0b013e318251035b","article-title":"Endometrial morphology after treatment of uterine fibroids with the selective progesterone receptor modulator, ulipristal acetate","volume":"31","author":"Williams","year":"2012","journal-title":"International Journal of Gynecological Pathology"},{"key":"10.1002\/14651858.CD010770.pub2-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1056\/NEJMoa1103180","article-title":"Ulipristal acetate versus leuprolide acetate for uterine fibroids","volume":"366","author":"Donnez","year":"2012","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD010770.pub2-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1093\/humrep\/dep100","article-title":"Mifepristone for treatment of uterine leiomyoma. A prospective randomized placebo controlled trial","volume":"24","author":"Engman","year":"2009","journal-title":"Human Reproduction"},{"key":"10.1002\/14651858.CD010770.pub2-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"361","DOI":"10.2147\/IJWH.S42770","article-title":"Mifepristone versus placebo to treat uterine myoma: a double-blind, randomized clinical trial","volume":"5","author":"Esteve","year":"2013","journal-title":"International Journal of Womens Health"},{"key":"10.1002\/14651858.CD010770.pub2-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"S41","DOI":"10.1016\/j.fertnstert.2006.07.114","article-title":"Effect of mifepristone on quality of life for women with symptomatic fibroids","volume":"86","author":"Eisinger","year":"2006","journal-title":"Fertility and Sterility"},{"key":"10.1002\/14651858.CD010770.pub2-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1097\/01.AOG.0000243776.23391.7b","article-title":"Effect of mifepristone for symptomatic leiomyomata on quality of life and uterine size: a randomized controlled trial","volume":"108","author":"Fiscella","year":"2006","journal-title":"Obstetrics and Gynecology"},{"key":"10.1002\/14651858.CD010770.pub2-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1097\/AOG.0b013e3181705d0e","article-title":"CDB-2914 for uterine leiomyomata treatment: a randomized controlled trial","volume":"111","author":"Levens","year":"2008","journal-title":"Obstetrics and Gynecology"},{"key":"10.1002\/14651858.CD010770.pub2-BIB0016|cit16","first-page":"95A","article-title":"Does the selective progesterone receptor modulator ulipristal normalize the uterine cavity in women with leiomyoma","volume":"1","author":"Levy","year":"2011","journal-title":"Reproductive Sciences"},{"key":"10.1002\/14651858.CD010770.pub2-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"e286","DOI":"10.1016\/j.fertnstert.2014.07.974","article-title":"Radiographic and histopathologic endometrial characteristics of women undergoing treatment with ulipristal acetate (UPA)","volume":"102","author":"Segal","year":"2014","journal-title":"Fertility and Sterility"},{"issue":"6","key":"10.1002\/14651858.CD010770.pub2-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"S91","DOI":"10.1016\/j.jmig.2015.08.245","article-title":"Low-dose mifepristone versus placebo to treat uterine myoma: a double-blind, randomized clinical trial","volume":"22","author":"Liu","year":"2015","journal-title":"Journal of Minimally Invasive Gynecology"},{"key":"10.1002\/14651858.CD010770.pub2-BIB0019|cit19","first-page":"88A","article-title":"Ulipristal acetate inhibits extracellular matrix production in human leiomyomas in vivo: a laboratory analysis of a randomized controlled trial","volume":"22","author":"Cox","year":"2015","journal-title":"Reproductive Sciences"},{"key":"10.1002\/14651858.CD010770.pub2-BIB0020|cit20","first-page":"150A","article-title":"Prolactin as a biomarker for tumor burden and response to UPA therapy in African American women with symptomatic leiomyoma","volume":"20","author":"Fru","year":"2013","journal-title":"Reproductive Sciences"},{"key":"10.1002\/14651858.CD010770.pub2-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"S96","DOI":"10.1016\/j.fertnstert.2012.07.351","article-title":"Efficacy of ulipristal acetate for the treatment of symptomatic uterine leiomyomas in African Americans","volume":"98","author":"Green","year":"2013","journal-title":"Fertility and Sterility"},{"key":"10.1002\/14651858.CD010770.pub2-BIB0022|cit22","first-page":"95A","article-title":"Does the selective progesterone receptor modulator ulipristal normalize the uterine cavity in women with leiomyoma","volume":"1","author":"Levy","year":"2011","journal-title":"Reproductive Sciences"},{"key":"10.1002\/14651858.CD010770.pub2-BIB0023|cit23","first-page":"P480","article-title":"Endocrine safety of ulipristal acetate, a selective progesterone receptor modulator (SPRM): results from two phase II randomised, placebo-controlled studies","volume":"22","author":"Nieman","year":"2010","journal-title":"Endocrine Abstracts"},{"key":"10.1002\/14651858.CD010770.pub2-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"767-72 e1-2","DOI":"10.1016\/j.fertnstert.2010.09.059","article-title":"Efficacy and tolerability of CDB-2914 treatment for symptomatic uterine fibroids: a randomized, double-blind, placebo-controlled, phase IIb study","volume":"95","author":"Nieman","year":"2011","journal-title":"Fertility and Sterility"},{"key":"10.1002\/14651858.CD010770.pub2-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"e286","DOI":"10.1016\/j.fertnstert.2014.07.974","article-title":"Radiographic and histopathologic endometrial characteristics of women undergoing treatment with ulipristal acetate (UPA)","volume":"102","author":"Segal","year":"2014","journal-title":"Fertility and Sterility"},{"key":"10.1002\/14651858.CD010770.pub2-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"S78","DOI":"10.1016\/j.fertnstert.2013.07.1924","article-title":"Effect of low dose mifepristone on uterine leiomyoma in reproductive age group","volume":"3","author":"Prasad","year":"2013","journal-title":"Fertility and Sterility"},{"key":"10.1002\/14651858.CD010770.pub2-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"1623-7; discuss","DOI":"10.1016\/S0002-9378(12)91826-8","article-title":"The effects of RU 486 and leuprolide acetate on uterine artery blood flow in the fibroid uterus: a prospective, randomized study","volume":"170","author":"Reinsch","year":"1994","journal-title":"American Journal of Obstetrics and Gynecology"},{"key":"10.1002\/14651858.CD010770.pub2-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1177\/1933719112463252","article-title":"Validation of the menstrual pictogram in women with leiomyomata associated with heavy menstrual bleeding","volume":"20","author":"Larsen","year":"2013","journal-title":"Reproductive Sciences"},{"key":"10.1002\/14651858.CD010770.pub2-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"4664","DOI":"10.1210\/jc.2008-1104","article-title":"Effects of the selective progesterone receptor modulator asoprisnil on uterine artery blood flow, ovarian activity, and clinical symptoms in patients with uterine leiomyomata scheduled for hysterectomy","volume":"93","author":"Wilkens","year":"2008","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"issue":"5","key":"10.1002\/14651858.CD010770.pub2-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"2226","DOI":"10.4049\/jimmunol.1300958","article-title":"Uterine NK cells regulate endometrial bleeding in women and are suppressed by the progesterone receptor modulator asoprisnil","volume":"191","author":"Wilkens","year":"2013","journal-title":"Journal of Immunology"},{"key":"10.1002\/14651858.CD010770.pub2-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1093\/humrep\/den494","article-title":"Effect of asoprisnil on uterine proliferation markers and endometrial expression of the tumour suppressor gene, PTEN","volume":"24","author":"Wilkens","year":"2009","journal-title":"Human Reproduction"},{"key":"10.1002\/14651858.CD010770.pub2-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1093\/humrep\/dem026","article-title":"The effects of the selective progesterone receptor modulator asoprisnil on the morphology of uterine tissues after 3 months treatment in patients with symptomatic uterine leiomyomata","volume":"22","author":"Williams","year":"2007","journal-title":"Human Reproduction"},{"key":"10.1002\/14651858.CD010770.pub2-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1097\/AOG.0b013e31818aa930","article-title":"Mifepristone for the treatment of uterine leiomyomas: a randomized controlled trial","volume":"112","author":"Carbonell Esteve","year":"2008","journal-title":"Obstetrics and Gynecology"},{"key":"10.1002\/14651858.CD010770.pub2-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"75","DOI":"10.2147\/IJWH.S28103","article-title":"Mifepristone 2.5 mg versus 5 mg daily in the treatment of leiomyoma before surgery","volume":"4","author":"Carbonell Esteve","year":"2012","journal-title":"International Journal of Womens Health"},{"key":"10.1002\/14651858.CD010770.pub2-BIB0035|cit35","article-title":"Treatment of uterine myoma with 2.5 or 5 mg mifepristone daily during 3 months with 9 months posttreatment followup: randomized clinical trial","volume":"Article ID 6490","author":"Carbonell","year":"2013","journal-title":"ISRN Obstetrics and Gynecology"},{"key":"10.1002\/14651858.CD010770.pub2-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"115","DOI":"10.2147\/IJWH.S33125","article-title":"Safety and effectiveness of different dosage of mifepristone for the treatment of uterine fibroids: a double-blind randomized clinical trial","volume":"5","author":"Carbonell","year":"2013","journal-title":"International Journal of Womens Health"},{"key":"10.1002\/14651858.CD010770.pub2-BIB0037|cit37","first-page":"301A","article-title":"Treatment of uterine leiomyomas with the novel selective progesterone receptor modulator (SPRM)","volume":"10","author":"Chwalisz","year":"2003","journal-title":"Journal of the Society for Gynecologic Investigation"},{"key":"10.1002\/14651858.CD010770.pub2-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1016\/j.fertnstert.2014.02.008","article-title":"Long-term treatment of uterine fibroids with ulipristal acetate","volume":"101","author":"Donnez","year":"2014","journal-title":"Fertility and Sterility"},{"key":"10.1002\/14651858.CD010770.pub2-BIB0039|cit39","first-page":"243","article-title":"Low-dose mifepristone for uterine leiomyomata","volume":"101","author":"Eisinger","year":"2003","journal-title":"Obstetrics & Gynecology"},{"key":"10.1002\/14651858.CD010770.pub2-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.jmig.2005.01.022","article-title":"Twelve-month safety and efficacy of low-dose mifepristone for uterine myomas","volume":"12","author":"Eisinger","year":"2005","journal-title":"Journal of Minimally Invasive Gynecology"},{"key":"10.1002\/14651858.CD010770.pub2-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.ejogrb.2011.12.018","article-title":"Treatment of uterine myoma with 5 or 10mg mifepristone daily during 6 months, post-treatment evolution over 12 months: double-blind randomised clinical trial","volume":"161","author":"Esteve","year":"2012","journal-title":"European Journal of Obstetrics, Gynecology, & Reproductive Biology"},{"key":"10.1002\/14651858.CD010770.pub2-BIB0042|cit42","first-page":"1154","article-title":"Low dose mifepristone in medical management of uterine leiomyoma - an experience from a tertiary care hospital from North India","volume":"137","author":"Kulshrestha","year":"2013","journal-title":"Indian Journal of Medical Research"},{"key":"10.1002\/14651858.CD010770.pub2-BIB0043|cit43","unstructured":"NCT00044876 Treatment of uterine fibroids with CDB-2914, an experimental selective progesterone receptor antagonist https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00044876"},{"key":"10.1002\/14651858.CD010770.pub2-BIB0044|cit44","unstructured":"NCT00152269 Treatment of uterine fibroids with asoprisnil (J867) https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00152269"},{"key":"10.1002\/14651858.CD010770.pub2-BIB0045|cit45","unstructured":"NCT00683917 Pharmacokinetics, safety and efficacy study of Proellex in pre-menopausal women with symptomatic uterine fibroids https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00683917"},{"key":"10.1002\/14651858.CD010770.pub2-BIB0046|cit46","unstructured":"NCT00702702 Safety and efficacy of Proellex in pre-menopausal anemic women with symptomatic uterine fibroids https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00702702"},{"key":"10.1002\/14651858.CD010770.pub2-BIB0047|cit47","unstructured":"NCT00735553 Evaluating the safety and efficacy of Proellex (CDB-4124) in premenopausal women with asymptomatic uterine fibroids https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00735553"},{"key":"10.1002\/14651858.CD010770.pub2-BIB0048|cit48","unstructured":"NCT00785356 Safety and efficacy of Proellex in pre-menopausal anemic women with symptomatic uterine fibroids https:\/\/clinicaltrialbase.com\/study\/NCT00785356"},{"key":"10.1002\/14651858.CD010770.pub2-BIB0049|cit49","unstructured":"NCT00853567 Evaluating the safety and efficacy of Proellex in premenopausal women with symptomatic uterine fibroids https:\/\/clinicaltrialbase.com\/study\/NCT00853567"},{"key":"10.1002\/14651858.CD010770.pub2-BIB0050|cit50","unstructured":"NCT00882258 Study of Proellex in pre-menopausal women with symptomatic uterine fibroids https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00882258"},{"key":"10.1002\/14651858.CD010770.pub2-BIB0051|cit51","unstructured":"NCT01069094 A Study of Progenta (CDB-4124) in pre-menopausal women with symptomatic leiomyomata https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01069094"},{"key":"10.1002\/14651858.CD010770.pub2-BIB0052|cit52","unstructured":"NCT01816815 Study in healthy tubal ligated women to evaluate pharmacodynamics, safety and pharmacokinetics of BAY1002670 https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01816815"},{"key":"10.1002\/14651858.CD010770.pub2-BIB0053|cit53","unstructured":"NCT02131662 Bay1002670, fibroids, safety and efficacy EU, US, Can, Jap (ASTEROID 1) https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02131662"},{"key":"10.1002\/14651858.CD010770.pub2-BIB0054|cit54","unstructured":"NCT02147158 A study of the safety and efficacy of intermittent ulipristal treatment of abnormal uterine bleeding associated with leiomyomas https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02147158 (first received 10 May 2014) 2016"},{"key":"10.1002\/14651858.CD010770.pub2-BIB0055|cit55","unstructured":"NCT02147197 A study of the efficacy and safety of a single ulipristal treatment course for the treatment of abnormal uterine bleeding associated with leiomyomas https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02147197"},{"key":"10.1002\/14651858.CD010770.pub2-BIB0056|cit56","unstructured":"NCT02288130 Ulipristal vs. GnRHa prior to laparoscopic myomectomy https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02288130"},{"key":"10.1002\/14651858.CD010770.pub2-BIB0057|cit57","unstructured":"NCT02323646 A phase 2 study to evaluate the safety and efficacy of Proellex (telapristone acetate) administered vaginally in the treatment of uterine fibroids https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02323646"},{"key":"10.1002\/14651858.CD010770.pub2-BIB0058|cit58","unstructured":"NCT02357563 Ulipristal acetate versus GnRH analogue and myometrial preservation https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02357563"},{"key":"10.1002\/14651858.CD010770.pub2-BIB0059|cit59","unstructured":"NCT02361879 Ulipristal acetate versus GnRH analogue treatment before hysteroscopic resection of uterine leiomyoma https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02361879"},{"key":"10.1002\/14651858.CD010770.pub2-BIB0060|cit60","unstructured":"NCT02361905 Ulipristal acetate for the preoperative management of hypoechoic cellular leiomyomas https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02361905"},{"key":"10.1002\/14651858.CD010770.pub2-BIB0061|cit61","unstructured":"NCT02425878 Ulipristal acetate 10 mg and assisted reproduction https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02425878"},{"key":"10.1002\/14651858.CD010770.pub2-BIB0062|cit62","unstructured":"NCT02465814 Assess safety and efficacy of vilaprisan in patients with uterine fibroids https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02465814"},{"issue":"1","key":"10.1002\/14651858.CD010770.pub2-BIB0063|cit63","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1067\/mob.2003.99","article-title":"High cumulative incidence of uterine leiomyoma in black and white women: ultrasound evidence","volume":"188","author":"Baird","year":"2003","journal-title":"American Journal of Obstetrics and Gynecology"},{"issue":"5","key":"10.1002\/14651858.CD010770.pub2-BIB0064|cit64","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1016\/j.fertnstert.2011.08.021","article-title":"Selective progesterone receptor modulators in reproductive medicine: pharmacology, clinical efficacy and safety","volume":"96","author":"Bouchard","year":"2011","journal-title":"Fertility and Sterility"},{"issue":"1","key":"10.1002\/14651858.CD010770.pub2-BIB0065|cit65","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/0168-8510(96)00822-6","article-title":"EuroQol: the current state of play","volume":"37","author":"Brooks","year":"1996","journal-title":"Health Policy"},{"issue":"14","key":"10.1002\/14651858.CD010770.pub2-BIB0066|cit66","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1056\/NEJMra1209993","article-title":"Uterine fibroids","volume":"369","author":"Bulun","year":"2013","journal-title":"New England Journal of Medicine"},{"issue":"3","key":"10.1002\/14651858.CD010770.pub2-BIB0067|cit67","doi-asserted-by":"crossref","first-page":"211.e1","DOI":"10.1016\/j.ajog.2011.12.002","article-title":"The estimated annual cost of uterine leiomyomata in the United States","volume":"206","author":"Cardozo","year":"2012","journal-title":"American Journal of Obstetrics and Gynecology"},{"issue":"3","key":"10.1002\/14651858.CD010770.pub2-BIB0068|cit68","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1210\/er.2005-0001","article-title":"Selective progesterone receptor modulator development and use in the treatment of leiomyomata and endometriosis","volume":"26","author":"Chwalisz","year":"2005","journal-title":"Endocrine Reviews"},{"key":"10.1002\/14651858.CD010770.pub2-BIB0069|cit69","volume-title":"Statistical Power Analysis in the Behavioral Sciences","author":"Cohen","year":"1988"},{"issue":"2","key":"10.1002\/14651858.CD010770.pub2-BIB0070|cit70","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.fertnstert.2014.10.038","article-title":"Efficacy and safety of repeated use of ulipristal acetate in uterine fibroids","volume":"103","author":"Donnez","year":"2015","journal-title":"Fertility and Sterility"},{"key":"10.1002\/14651858.CD010770.pub2-BIB0071|cit71","unstructured":"GRADE Working Group, McMaster University GRADEpro GDT 2014"},{"issue":"2","key":"10.1002\/14651858.CD010770.pub2-BIB0072|cit72","doi-asserted-by":"crossref","first-page":"e0149631","DOI":"10.1371\/journal.pone.0149631","article-title":"Medical therapies for uterine fibroids - a systematic review and network meta-analysis of randomised controlled trials","volume":"11","author":"Gurusamy","year":"2016","journal-title":"PloS one"},{"key":"10.1002\/14651858.CD010770.pub2-BIB0073|cit73","article-title":"Cochrane handbook for systematic reviews of interventions","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]","author":"Higgins","year":"2011. www.cochrane-handbook.org"},{"key":"10.1002\/14651858.CD010770.pub2-BIB0074|cit74","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1111\/j.1471-0528.1990.tb16249.x","article-title":"Assessment of menstrual blood loss using a pictorial chart","volume":"97","author":"Higham","year":"1990","journal-title":"BJOG"},{"issue":"6","key":"10.1002\/14651858.CD010770.pub2-BIB0075|cit75","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1210\/en.2009-1225","article-title":"Progesterone is essential for maintenance and growth of uterine leiomyoma","volume":"151","author":"Ishikawa","year":"2010","journal-title":"Endocrinology"},{"issue":"2","key":"10.1002\/14651858.CD010770.pub2-BIB0076|cit76","doi-asserted-by":"crossref","first-page":"91","DOI":"10.3109\/09513590.2015.1106471","article-title":"Ulipristal acetate for uterine fibroids: a systematic review and meta-analysis","volume":"32","author":"Kalampokas","year":"2016","journal-title":"Gynecological Endocrinology"},{"issue":"9","key":"10.1002\/14651858.CD010770.pub2-BIB0077|cit77","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007692.pub2","article-title":"Danazol for uterine fibroids","author":"Ke","year":"2011","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD010770.pub2-BIB0078|cit78","doi-asserted-by":"crossref","unstructured":"Khan K The CROWN Initiative: journal editors invite researchers to develop core outcomes in women's health BJOG 2014 1181 2","DOI":"10.1111\/1471-0528.12929"},{"issue":"2","key":"10.1002\/14651858.CD010770.pub2-BIB0079|cit79","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD000547","article-title":"Pre-operative GnRH analogue therapy before hysterectomy or myomectomy for uterine fibroids","author":"Lethaby","year":"2001","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"1","key":"10.1002\/14651858.CD010770.pub2-BIB0080|cit80","first-page":"CR24","article-title":"Hysterectomy surveillance in the United States, 1997 through 2005","volume":"14","author":"Merrill","year":"2008","journal-title":"Medical Science Monitor"},{"issue":"5","key":"10.1002\/14651858.CD010770.pub2-BIB0081|cit81","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1016\/j.fertnstert.2016.06.012","article-title":"Role of ethnicity in treating uterine fibroids with ulipristal acetate","volume":"106","author":"Murji","year":"2016","journal-title":"Fertility and Sterility"},{"issue":"5","key":"10.1002\/14651858.CD010770.pub2-BIB0082|cit82","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1038\/modpathol.2008.19","article-title":"The spectrum of endometrial pathology induced by progesterone receptor modulators","volume":"21","author":"Mutter","year":"2008","journal-title":"Modern Pathology"},{"key":"10.1002\/14651858.CD010770.pub2-BIB0083|cit83","unstructured":"Nordic Cochrane Centre, The Cochrane Collaboration Review Manager 5 (RevMan 5) 2014"},{"issue":"4","key":"10.1002\/14651858.CD010770.pub2-BIB0084|cit84","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1177\/1933719111432867","article-title":"Medical treatment of uterine leiomyoma","volume":"19","author":"Sabry","year":"2012","journal-title":"Reproductive Sciences"},{"issue":"2","key":"10.1002\/14651858.CD010770.pub2-BIB0085|cit85","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD008994.pub2","article-title":"Progestogens or progestogen-releasing intrauterine systems for uterine fibroids","author":"Sangkomkamhang","year":"2013","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"2","key":"10.1002\/14651858.CD010770.pub2-BIB0086|cit86","first-page":"290","article-title":"The UFS-QOL, a new disease-specific symptom and health-related quality of life questionnaire for leiomyomata","volume":"99","author":"Spies","year":"2002","journal-title":"Obstetrics and Gynecology"},{"issue":"2","key":"10.1002\/14651858.CD010770.pub2-BIB0087|cit87","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1097\/00003081-200106000-00022","article-title":"Clinical symptomatology of uterine leiomyomas","volume":"44","author":"Stovall","year":"2001","journal-title":"Clinical Obstetrics and Gynecology"},{"issue":"1","key":"10.1002\/14651858.CD010770.pub2-BIB0088|cit88","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1177\/1933719114553451","article-title":"Unbiased and efficient estimation of the volume of the fibroid uterus using the Cavalieri method and magnetic resonance imaging","volume":"22","author":"Thrippleton","year":"2015","journal-title":"Reproductive Sciences"},{"issue":"8","key":"10.1002\/14651858.CD010770.pub2-BIB0089|cit89","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007687.pub2","article-title":"Mifepristone for uterine fibroids","author":"Tristan","year":"2012","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"1","key":"10.1002\/14651858.CD010770.pub2-BIB0090|cit90","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1001\/jama.2008.791","article-title":"A 41-year-old woman with menorrhagia, anemia, and fibroids: review of treatment of uterine fibroids","volume":"301","author":"Voorhis","year":"2009","journal-title":"JAMA"},{"issue":"9","key":"10.1002\/14651858.CD010770.pub2-BIB0091|cit91","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/14728222.2016.1180368","article-title":"Selective progesterone receptor modulators (SPRMs): progesterone receptor action, mode of action on the endometrium and treatment options in gynecological therapies","volume":"20","author":"Wagenfeld","year":"2016","journal-title":"Expert Opinion on Therapeutic Targets"},{"issue":"2","key":"10.1002\/14651858.CD010770.pub2-BIB0092|cit92","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1097\/01.AOG.0000136079.62513.39","article-title":"Uterine myomas: an overview of development, clinical features, and management","volume":"104","author":"Wallach","year":"2004","journal-title":"Obstetrics and Gynecology"},{"issue":"6","key":"10.1002\/14651858.CD010770.pub2-BIB0093|cit93","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1097\/00005650-199206000-00002","article-title":"The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection","volume":"30","author":"Ware","year":"1992","journal-title":"Medical Care"},{"issue":"7","key":"10.1002\/14651858.CD010770.pub2-BIB0094|cit94","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1089\/jwh.2006.15.818","article-title":"Uterine fibroids: a review of health-related quality of life assessment","volume":"15","author":"Williams","year":"2006","journal-title":"Journal of Womens Health"},{"key":"10.1002\/14651858.CD010770.pub2-BIB0095|cit95","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/S0015-0282(01)01847-7","article-title":"Determination of total menstrual blood loss","volume":"76","author":"Wyatt","year":"2001","journal-title":"Fertility and Sterility"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1002\/14651858.CD010770.pub2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,9]],"date-time":"2021-08-09T18:48:19Z","timestamp":1628534899000},"score":1,"resource":{"primary":{"URL":"https:\/\/doi.wiley.com\/10.1002\/14651858.CD010770.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Gynaecology and Fertility Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2017,4,26]]},"references-count":95,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2017,4]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd010770.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,4,26]]}}}